Loading data
CGENNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 72.76 m USD | 27.86 m USD | 33.46 m USD | 7.5 m USD | 6 m USD |
| Cost of revenue | 9.25 m USD | 7.93 m USD | 2 m USD | 975 k USD | 680 k USD |
| Gross profit | 63.51 m USD | 19.93 m USD | 31.46 m USD | 6.53 m USD | 5.32 m USD |
| Research and development expense | 22.76 m USD | 24.81 m USD | 34.47 m USD | 30.65 m USD | 28.69 m USD |
| Operating profit | 31.33 m USD | -14.89 m USD | -12.99 m USD | -35.37 m USD | -35.07 m USD |
| Profit before tax | 35.4 m USD | -9.71 m USD | -9.78 m USD | -33.64 m USD | -34.2 m USD |
| Income tax expense | 54 k USD | 4.52 m USD | 8.97 m USD | 58 k USD | 0 USD |
| Net income (reported basis) | 35.34 m USD | -14.23 m USD | -18.75 m USD | -33.69 m USD | -34.2 m USD |
| Net income attributable to common shareholders | 35.34 m USD | -14.23 m USD | -18.75 m USD | — | — |
| Basic earnings per share | 0.38 USD/share | -0.16 USD/share | -0.21 USD/share | -0.39 USD/share | -0.41 USD/share |
| Diluted earnings per share | 0.38 USD/share | -0.16 USD/share | -0.21 USD/share | -0.39 USD/share | -0.41 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.